skip to content


Issue No. 12 | May 3, 2013

News and Features

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Seeks Nominations for the Non-Governmental Co-Chair of the Panel

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is seeking nominations for the non-governmental co-chair of the Panel.

The Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health. The Panel writes and updates the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. The latest guideline was published on February 12, 2013, and can be found at

The Panel is led by two co-chairs: an HHS-appointed co-chair and a non-governmental co-chair. The Panel co-chairs are supported by an executive secretary and over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States.

The co-chairs of the Panel provide overall leadership for Panel direction and activities; specifically, they administer and direct Panel proceedings, facilitate dynamic and productive deliberations among Panel members, and, as indicated, develop consensus recommendations and updates on the basis of objective evaluation of scientific information available in the public domain. The Panel co-chairs serve as the official voice of the Panel for public statements relating to the guidelines. The non-governmental co-chair also serves as an ex-officio member of OARAC.

The successful candidate must be a recognized leader in clinical care or clinical research in HIV and antiretroviral therapy, must have experience in clinical practice guidelines development, and must be free of any financial relationship with manufacturers of antiretroviral agents or related diagnostics.

The candidate selected will not be compensated for time commitment related to Panel activities, and travel support for participation is not provided.

Potential candidates can self-nominate or can be nominated by a colleague. The nomination should include a curriculum vitae and a letter of nomination (or letter of interest) with specific reference to how the nominee’s expertise and experience will contribute to leadership of the Panel. Please submit nominations by May 31, 2013, to Alice Pau, PharmD, Executive Secretary, Division of Clinical Research, NIAID-NIH, Bldg 10, Rm 11C103, Bethesda, MD 20892; e-mail:

Recent HIV/AIDS News

  • April 30, 2013: U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for HIV

    “The U.S. Preventive Services Task Force (Task Force) today released its final recommendation statement on screening for HIV. The Task Force recommends that clinicians screen all people aged 15 to 65, as well as younger adolescents and older adults who are at an increased risk for HIV infection.”

    Read the blog post.
  • April 25, 2013: Prezista (Darunavir) Labeling Changes

    “On April 24, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to update labeling with 48 week data from study TMC114-C228 for HIV-1 treatment experienced pediatric patients three to less than 6 years of age.” 

    Read the FDA announcement.
  • April 25, 2013: NIH Discontinues Immunizations in HIV Vaccine Study

    “The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who became infected with HIV.”

    Read the NIAID press release.
  • April 22, 2013: Anti-HIV Therapy Appears to Protect Children’s Hearts, NIH Network Study Shows

    “For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were available, according to researchers in a National Institutes of Health network study.”

    Read the NIH press release.

CDC Launches Newly Redesigned HIV Website

The Centers for Disease Control and Prevention (CDC) recently launched its newly redesigned HIV website. Updates to the site include expanded resources for the general public, an improved funding section, and a calendar for upcoming HIV-related trainings and conferences. The redesigned site is also optimized for use on mobile devices. Visit the site today to locate and share helpful HIV-related resources!